AmeriHealth published a new medical policy on July 1, 2022, to further communicate its coverage position on the drug aducanumab (Aduhelm) for the treatment of Alzheimer disease.
Effective June 7, 2021, the use of Aduhelm is considered experimental/investigational and therefore not covered for all indications, including the treatment of Alzheimer disease.
For more information, please view Medical Policy #08.01.93: Aducanumab (Aduhelm) for Alzheimer Disease.